Furthermore, Kwon and colleagues demonstrated in a large population of BC patients (n = 284), a gradual increase of FDG uptake (measured as SUVmax) from hormonal types to triple negative, also suggesting a trend for higher SUV in HER2-positive tumors compared to tumors without HER2 (p  =  0.093) [36]. This evidence concerns the gene ERBB2 and breast cancer.